newsfilter
← Latest News
GlobeNewswire·

20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

AIDX
  • 20/20 BioLabs, Inc. (NASDAQ: AIDX) entered a standstill agreement with Streeterville Capital, LLC effective July 16, 2026.
  • The agreement restricts Streeterville from converting Series E Convertible Preferred Stock into common stock for 120 days unless the stock trades at least 10% above the Nasdaq Rule 5635 "Minimum Price."
  • This restriction aims to mitigate potential near-term dilution while preserving existing rights and obligations under related transaction documents.
  • The standstill terminates immediately upon any breach of the agreement or Event of Default as defined in the Series E Preferred Stock Certificate of Designation.
  • Upon expiration or termination, Streeterville may resume conversions in accordance with applicable transaction documents.
  • A Current Report on Form 8-K detailing the agreement will be filed with the U.S. Securities and Exchange Commission.
  • 20/20 BioLabs develops AI-powered blood tests under the OneTest brand for cancer detection and longevity, processed in its CAP-accredited, CLIA-licensed laboratory in Gaithersburg, Maryland.